{"id":{"repo_id":"usf","oai_identifier":"oai:digitalcommons.usf.edu:etd-11884"},"canonical_url":"https://search.ndltd.org/etd/usf/oai:digitalcommons.usf.edu:etd-11884","repository":{"repo_id":"usf","name":"University of South Florida","base_url":"https://digitalcommons.usf.edu/do/oai/"},"display":{"title":"MALAT1 Mediates TET2 Loss of Function-Driven Oncogenic Inflammation Via RNA Shielding of NF- Kappa B P65","abstract":"TET2 is a dioxygenase that regulates gene expression and hematopoiesis by oxidizing 5-methylcytosine residues on DNA to 5-hydroxymethylcytosine. TET2 mutations are common genetic events in hematological disorders. For example, TET2 is the most frequently mutated gene in Chronic Myelomonocytic Leukemia and occurs in about 33% of other myeloid malignancies. It is also the second commonest mutation in clonal hematopoiesis of indeterminate potential (CHIP), a common premalignant condition in the elderly. TET2 mutations arise in founding clones and are implicated in many non-hematological sequelae seen in CHIP like atherosclerotic disease, chronic liver disease, and severe microbial infections. The development of TET2-deficient hematological disorders as well as their sequelae is associated with the potentiation of inflammatory circuits. However, while multiple studies show the response of Tet2-deficient cells to heightened inflammation, the major downstream effector responsible for potentiating this oncogenic inflammation is unknown. To address this, we used scRNA and scATAC-seq in COVID-19 patients with and without TET2 mutations reasoning that inflammation from COVID-19 may unmask downstream targets of TET2 mutations. Using this approach, we identified MALAT1, a druggable lncRNA, as a central downstream effector of TET2 mutations that is both necessary and sufficient to induce inflammatory Tet2-deficient phenotypes. We also show TET2 deficiency increases MALAT1 expression by reducing chromatin accessibility of EGR1. Finally, we describe a “shielding” interaction between MALAT1 and P65 leading to reduced PP2A dephosphorylation, thus preventing resolution of inflammatory signaling and promoting the development of Tet2-deficient phenotypes. This work nominates MALAT1 as a viable therapeutic target in TET2-mutated disorders.","abstract_html":"TET2 is a dioxygenase that regulates gene expression and hematopoiesis by oxidizing 5-methylcytosine residues on DNA to 5-hydroxymethylcytosine. TET2 mutations are common genetic events in hematological disorders. For example, TET2 is the most frequently mutated gene in Chronic Myelomonocytic Leukemia and occurs in about 33% of other myeloid malignancies. It is also the second commonest mutation in clonal hematopoiesis of indeterminate potential (CHIP), a common premalignant condition in the elderly. TET2 mutations arise in founding clones and are implicated in many non-hematological sequelae seen in CHIP like atherosclerotic disease, chronic liver disease, and severe microbial infections. The development of TET2-deficient hematological disorders as well as their sequelae is associated with the potentiation of inflammatory circuits. However, while multiple studies show the response of Tet2-deficient cells to heightened inflammation, the major downstream effector responsible for potentiating this oncogenic inflammation is unknown. To address this, we used scRNA and scATAC-seq in COVID-19 patients with and without TET2 mutations reasoning that inflammation from COVID-19 may unmask downstream targets of TET2 mutations. Using this approach, we identified MALAT1, a druggable lncRNA, as a central downstream effector of TET2 mutations that is both necessary and sufficient to induce inflammatory Tet2-deficient phenotypes. We also show TET2 deficiency increases MALAT1 expression by reducing chromatin accessibility of EGR1. Finally, we describe a “shielding” interaction between MALAT1 and P65 leading to reduced PP2A dephosphorylation, thus preventing resolution of inflammatory signaling and promoting the development of Tet2-deficient phenotypes. This work nominates MALAT1 as a viable therapeutic target in TET2-mutated disorders.","abstract_has_math":false,"creators":["Ben-Crentsil, Nana Adjoa"],"institution":"University of South Florida","degree_name":"Doctor of Philosophy (Ph.D.)","degree_level":"Dissertation","degree_discipline":"Molecular Biosciences","degree_department":null,"school":null,"contributors":["Eric Padron, M.D.","Robert Deschenes, Ph.D.","Florian Karreth, Ph.D.","Hana Totary-Jain, Ph.D.","Niketa Patel, Ph.D.","Subhra Mohapatra, Ph.D."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024-09-09T07:00:00Z","date_published":"2024-09-09T07:00:00Z","updated_at":"2026-11-19T08:50:05Z","subjects":["Inflammation","myeloproliferation","Interleukin 6","Leukemia","Clonal Hematopoiesis","Molecular Biology"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.usf.edu/etd/10597","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://digitalcommons.usf.edu/etd/10597","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://digitalcommons.usf.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Adigitalcommons.usf.edu%3Aetd-11884","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Eric Padron, M.D.","Robert Deschenes, Ph.D.","Florian Karreth, Ph.D.","Hana Totary-Jain, Ph.D.","Niketa Patel, Ph.D.","Subhra Mohapatra, Ph.D."]},{"key":"dc:creator","label":"Author","values":["Ben-Crentsil, Nana Adjoa"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2024-09-09T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Molecular Biosciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation","Ph.D."]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (Ph.D.)"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of South Florida"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Inflammation","myeloproliferation","Interleukin 6","Leukemia","Clonal Hematopoiesis","Molecular Biology"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.usf.edu/etd/10597"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["TET2 is a dioxygenase that regulates gene expression and hematopoiesis by oxidizing 5-methylcytosine residues on DNA to 5-hydroxymethylcytosine. TET2 mutations are common genetic events in hematological disorders. For example, TET2 is the most frequently mutated gene in Chronic Myelomonocytic Leukemia and occurs in about 33% of other myeloid malignancies. It is also the second commonest mutation in clonal hematopoiesis of indeterminate potential (CHIP), a common premalignant condition in the elderly. TET2 mutations arise in founding clones and are implicated in many non-hematological sequelae seen in CHIP like atherosclerotic disease, chronic liver disease, and severe microbial infections. The development of TET2-deficient hematological disorders as well as their sequelae is associated with the potentiation of inflammatory circuits. However, while multiple studies show the response of Tet2-deficient cells to heightened inflammation, the major downstream effector responsible for potentiating this oncogenic inflammation is unknown. To address this, we used scRNA and scATAC-seq in COVID-19 patients with and without TET2 mutations reasoning that inflammation from COVID-19 may unmask downstream targets of TET2 mutations. Using this approach, we identified MALAT1, a druggable lncRNA, as a central downstream effector of TET2 mutations that is both necessary and sufficient to induce inflammatory Tet2-deficient phenotypes. We also show TET2 deficiency increases MALAT1 expression by reducing chromatin accessibility of EGR1. Finally, we describe a “shielding” interaction between MALAT1 and P65 leading to reduced PP2A dephosphorylation, thus preventing resolution of inflammatory signaling and promoting the development of Tet2-deficient phenotypes. This work nominates MALAT1 as a viable therapeutic target in TET2-mutated disorders."]},{"key":"dc:title","label":"Title","values":["MALAT1 Mediates TET2 Loss of Function-Driven Oncogenic Inflammation Via RNA Shielding of NF- Kappa B P65"]}]}],"canonical_facts":{"dc:contributor":["Eric Padron, M.D.","Robert Deschenes, Ph.D.","Florian Karreth, Ph.D.","Hana Totary-Jain, Ph.D.","Niketa Patel, Ph.D.","Subhra Mohapatra, Ph.D."],"dc:creator":["Ben-Crentsil, Nana Adjoa"],"dc:date":["2024-09-09T07:00:00Z"],"dc:description":["TET2 is a dioxygenase that regulates gene expression and hematopoiesis by oxidizing 5-methylcytosine residues on DNA to 5-hydroxymethylcytosine. TET2 mutations are common genetic events in hematological disorders. For example, TET2 is the most frequently mutated gene in Chronic Myelomonocytic Leukemia and occurs in about 33% of other myeloid malignancies. It is also the second commonest mutation in clonal hematopoiesis of indeterminate potential (CHIP), a common premalignant condition in the elderly. TET2 mutations arise in founding clones and are implicated in many non-hematological sequelae seen in CHIP like atherosclerotic disease, chronic liver disease, and severe microbial infections. The development of TET2-deficient hematological disorders as well as their sequelae is associated with the potentiation of inflammatory circuits. However, while multiple studies show the response of Tet2-deficient cells to heightened inflammation, the major downstream effector responsible for potentiating this oncogenic inflammation is unknown. To address this, we used scRNA and scATAC-seq in COVID-19 patients with and without TET2 mutations reasoning that inflammation from COVID-19 may unmask downstream targets of TET2 mutations. Using this approach, we identified MALAT1, a druggable lncRNA, as a central downstream effector of TET2 mutations that is both necessary and sufficient to induce inflammatory Tet2-deficient phenotypes. We also show TET2 deficiency increases MALAT1 expression by reducing chromatin accessibility of EGR1. Finally, we describe a “shielding” interaction between MALAT1 and P65 leading to reduced PP2A dephosphorylation, thus preventing resolution of inflammatory signaling and promoting the development of Tet2-deficient phenotypes. This work nominates MALAT1 as a viable therapeutic target in TET2-mutated disorders."],"dc:identifier":["https://digitalcommons.usf.edu/etd/10597"],"dc:subject":["Inflammation","myeloproliferation","Interleukin 6","Leukemia","Clonal Hematopoiesis","Molecular Biology"],"dc:title":["MALAT1 Mediates TET2 Loss of Function-Driven Oncogenic Inflammation Via RNA Shielding of NF- Kappa B P65"],"thesis:degree_discipline":["Molecular Biosciences"],"thesis:degree_level":["Dissertation","Ph.D."],"thesis:degree_name":["Doctor of Philosophy (Ph.D.)"],"thesis:institution_name":["University of South Florida"]},"updated_at":"2026-11-19T08:50:05Z"}